Artelo Biosciences
ARTL
15 hedge funds and large institutions have $443K invested in Artelo Biosciences in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
17% less funds holding
Funds holding: 18 → 15 (-3)
33% less capital invested
Capital invested by funds: $659K → $443K (-$216K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$25.3K |
| 2 |
VF
Virtu Financial
New York
|
+$14.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$11.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.98K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$6.59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$82K |
| 2 |
HF
HRT Financial
New York
|
-$12K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.41K |
| 5 |
Bank of New York Mellon
New York
|
-$197 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $217K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $59K | +$6.98K | +71 | +11% |
|
|
SCA
3
Snowden Capital Advisors
New York
| $34K | – | – | – |
|
|
4
Bank of New York Mellon
New York
| $27K | -$197 | -2 | -0.6% |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $25K | +$25.3K | +257 | +643% |
|
6
Northern Trust
Chicago,
Illinois
| $20K | – | – | – |
|
|
VF
7
Virtu Financial
New York
| $20K | +$14.4K | +146 | +166% |
|
|
8
UBS Group
Zurich,
Switzerland
| $16K | +$11.1K | +113 | +166% |
|
|
9
HighTower Advisors
Chicago,
Illinois
| $14K | +$6.59K | +67 | +70% |
|
|
SG
10
StoneX Group
New York
| $4.75K | +$5.51K | +56 | New |
|
11
State Street
Boston,
Massachusetts
| $4K | – | – | – |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| $2K | -$5.41K | -55 | -75% |
|
|
13
Renaissance Technologies
New York
| – | -$82K | -676 | Closed |
|
|
HF
14
HRT Financial
New York
| – | -$12K | -104 | Closed |
|
|
TSS
15
Two Sigma Securities
New York
| – | -$8K | -68 | Closed |
|
ARTL Hedge Fund Activity: Q2 2022 in Review
15 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q2 2022, worth a combined $443K — down 33% from $659K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ARTL and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Susquehanna International Group, adding an estimated $25.3K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $82K sold.
- 15 institutional investors held Artelo Biosciences (ARTL) as of Q2 2022, down from 18 in Q1 2022.
- Funds reported $443K of Artelo Biosciences stock for Q2 2022, down 33% quarter-over-quarter.
- 1 fund opened new Artelo Biosciences positions in Q2 2022 and 3 closed out, a net change of -2 holders.
- The largest Artelo Biosciences buyer in Q2 2022 was Susquehanna International Group, an estimated $25.3K added.
- The largest Artelo Biosciences seller in Q2 2022 was Renaissance Technologies, an estimated $82K sold.
Based on aggregated 13F filings for Q2 2022.